Alterome Therapeutics Welcomes Andrew S. Chi, M.D., Ph.D., as Chief Medical Officer
Alterome Therapeutics, Inc., a next-generation precision oncology company pioneering the development of alteration-specific targeted therapies for the treatment of cancer, today announced the appointment of Andrew S. Chi, M.D., Ph.D., as its Chief Medical Officer.
Alterome Therapeutics Establishes Scientific Advisory Board Comprised of Renowned Oncology Experts
Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of alteration-specific targeted therapies for the treatment of cancer, today announced the formation of the Company’s Scientific Advisory Board (SAB) with four esteemed oncology experts.
Alterome Therapeutics Extends Series A to Nearly $100 Million to Advance Alteration-Specific Cancer Therapies
$35 million extension round led by new investor Colt Ventures and co-led by existing investor OrbiMed with participation from all existing investors
Mysterious OrbiMed-backed biotech nears $100M in funding, hints at plans to go after ‘undruggable 3.0’
While the biotech put out a press release for its $64 million Series A, led by OrbiMed, it launched without a website and didn’t elaborate on its science beyond “alteration-specific targeted therapies for the treatment of cancer.”
OrbiMed takes point on a new biotech launch, but almost everything remains secret for now
If you missed the news of a new company launch backed by blue-chip investor OrbiMed early Wednesday morning, that was by design. Alterome Therapeutics quietly emerged from stealth with $64 million in its Series A…
Alterome Therapeutics Launches With $64M Series A Financing
Alterome Therapeutics, Inc., a biopharmaceutical company developing alteration-specific targeted therapies for the treatment of cancer, announced the closing of a $64M Series A financing…